Tumor-derived transforming growth factor-β1 and interleukin-6 are chemotactic for lymphokine-activated killer cells
- 1 June 1994
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 57 (5) , 696-700
- https://doi.org/10.1002/ijc.2910570515
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- High deformability and motility of lymphokine-activated killer cells in vitro and in vivoJournal of Leukocyte Biology, 1992
- Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of Experimental Medicine, 1991
- In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing ratsCellular Immunology, 1990
- Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in cultureJournal of Cellular Physiology, 1989
- Functional discrimination between interleukin 6 and interleukin 1European Journal of Immunology, 1988
- B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells.Proceedings of the National Academy of Sciences, 1987
- Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.Proceedings of the National Academy of Sciences, 1987
- Production of hybridoma growth factor by human monocytesEuropean Journal of Immunology, 1987
- Rapid colorimetric assay for cell growth and survivalJournal of Immunological Methods, 1986
- A Growth-Factor Dependent B-Cell HybridomaPublished by Springer Nature ,1986